Citations

Clear

6273 citation(s) found for "To, Andrew".

P3‐018: INFLUENCE OF RARE PSEN1 VARIANTS ON QUANTITATIVE STRUCTURAL IMAGING AND CSF PHENOTYPES IN LATE ONSET ALZHEIMER'S DISEASE
Aisen, Paul, Petersen, Ronald , Shaw, Leslie M. , Trojanowski, John Q., Weiner, Michael W. , Nho, Kwangsik T. , Kim, Sungeun , Risacher, Shannon L. , Shen, Li , Foroud, Tatiana , Jack, Clifford R. , Trojanowski, John Q., Green, Robert C. , Toga, Arthur W. , Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_17 | Pages: No page available

10.1016/j.jalz.2014.05.1105 Get It

O2‐03‐03: BIN1 AND CR1 VARIANTS AFFECT COGNITIVE PERFORMANCE, NEURODEGENERATION, AND BRAIN AMYLOIDOSIS IN ADNI SUBJECTS
Blanken, Anna E., Torosyan, Nare , Manne, Manogna, Durcanova, Beata, Apostolova, Liana G. , Silverman, Daniel H.S. , Saykin, Andrew J. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_2 | Pages: No page available

10.1016/j.jalz.2014.04.169 Get It

IC‐P‐096: INCREASED AMYLOID DEPOSITION IN OLDER ADULTS AT RISK FOR PROGRESSION TO ALZHEIMER'S DISEASE DUE TO GENETIC BACKGROUND AND/OR THE PRESENCE OF SIGNIFICANT MEMORY CONCERNS
Kim, Sungeun , West, John D. , Petersen, Ronald C. , Aisen, Paul , Jagust, William J. , Weiner, Michael W. , Risacher, Shannon L. , Nho, Kwangsik T. , Wang, Yang , Jack, Clifford R. , Koeppe, Robert A. , Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_6 | Pages: No page available

10.1016/j.jalz.2014.05.101 Get It

O3‐03‐02: TWO‐YEAR LONGITUDINAL CHANGE IN AMYLOID DEPOSITION, GLUCOSE METABOLISM, AND HIPPOCAMPAL ATROPHY IN ADNI‐2 PARTICIPANTS: RELATION TO GENETIC RISK
Kim, Sungeun , West, John D. , Petersen, Ronald C. , Aisen, Paul , Jagust, William J. , Koeppe, Robert, Weiner, Michael W. , Risacher, Shannon L. , Nho, Kwangsik T. , Jack, Clifford R. , Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_3 | Pages: No page available

10.1016/j.jalz.2014.04.281 Get It

P3‐024: NEXT‐GENERATION SEQUENCING OF THE BCHE LOCUS IDENTIFIES A FUNCTIONAL SNP ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS AND AGE OF ONSET
Kim, Sungeun , Aisen, Paul, Huentelman, Matthew J. , Jagust, William J. , Petersen, Ronald Carl, Shaw, Leslie M. , Trojanowski, John Q. , Weiner, Michael W. , Ramanan, Vijay K. , Nho, Kwangsik T. , Risacher, Shannon L. , Shen, Li , Swaminathan, Shanker , Foroud, Tatiana , Håkonarson, Håkon , Jack, Clifford R. , Potkin, Steven G. , Green, Robert C. , Toga, Arthur W. , Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_17 | Pages: No page available

10.1016/j.jalz.2014.05.1111 Get It

Reduced junctional Na+/Ca2+-exchanger activity contributes to sarcoplasmic reticulum Ca2+ leak in junctophilin-2-deficient mice
Landstrom, Andrew P. , Wang, Qiongling, Munro, Michelle L. , Beavers, David L. , Ackerman, Michael J. , Soeller, Christian , Wehrens, Xander H.T. , Wang, Wei , Landstrom, Andrew P , Wehrens, Xander H T

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | September 6, 2014 | Volume: 307 | Issue: 9 | Pages: H1317-H1326

10.1152/ajpheart.00413.2014 | PMID 25193470 Get It

Expression silencing of junctophilin-2 (JPH2) in mouse heart leads to ryanodine receptor type 2 (RyR2)-mediated sarcoplasmic reticulum (SR) Ca2+ leak and rapid development of heart failure. The mechanism and physiological significance of JPH2 in regulating RyR2-mediated SR Ca2+ leak remains elusive. We sought to elucidate the role of JPH2 in regulating RyR2-mediated SR Ca2+ release in the setting of cardiac failure. Cardiac myocytes isolated from tamoxifen-inducible conditional knockdown mice of JPH2 (MCM-shJPH2) were subjected to confocal Ca2+ imaging. MCM-shJPH2 cardiomyocytes exhibited an increased spark frequency width with altered spark morphology, which caused increased SR Ca2+ leakage. Single channel studies identified an increased RyR2 open probability in MCM-shJPH2 mice. The increase in spark frequency and width was observed only in MCM-shJPH2 and not found in mice with increased RyR2 open probability with native JPH2 expression. Na+/Ca2+-exchanger (NCX) activity was reduced by 50% in MCM-shJPH2 with no detectable change in NCX expression. Additionally, 50% inhibition of NCX through Cd2+ administration alone was sufficient to increase spark width in myocytes obtained from wild-type mice. Additionally, superresolution analysis of RyR2 and NCX colocalization showed a reduced overlap between RyR2 and NCX in MCM-shJPH2 mice. In conclusion, decreased JPH2 expression causes increased SR Ca2+ leakage by directly increasing open probability of RyR2 and by indirectly reducing junctional NCX activity through increased dyadic cleft Ca2+. This demonstrates two novel and independent cellular mechanisms by which JPH2 regulates RyR2-mediated SR Ca2+ leak and heart failure development.
Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma
Chawla, Sant P. , Cranmer, Lee D. , Reed, Damon R. , Okuno, Scott H. , Butrynski, James E., Hendifar, Andrew , Kroll, Stew, Ganjoo, Kristen N. , Van Tine, Brian A, Adkins, Douglas R. , Tine, Brian A. Van , Reed, Damon R

Mayo Clinic

Journal of Clinical Oncology | September 3, 2014 | Volume: 32 | Issue: 29 | Pages: 3299-3306

10.1200/jco.2013.54.3660 | PMID 25185097 Get It

Purpose TH-302, a prodrug of the cytotoxic alkylating agent bromo-isophosphoramide mustard, is preferentially activated in hypoxic conditions. This phase II study investigated TH-302 in combination with doxorubicin, followed by single-agent TH-302 maintenance therapy in patients with first-line advanced soft tissue sarcoma (STS) to assess progression-free survival (PFS), response rate, overall survival, safety, and tolerability. Patients and Methods In this open-label phase II study, TH-302 300 mg/m 2 was administered intravenously on days 1 and 8 with doxorubicin 75 mg/m 2 on day 1 of each 21-day cycle. After six cycles, patients with stable and/or responding disease could receive maintenance monotherapy with TH-302. Results Ninety-one patients initiated TH-302 plus doxorubicin induction treatment. The PFS rate at 6 months (primary efficacy measure) was 58% (95% CI, 46% to 68%). Median PFS was 6.5 months (95% CI, 5.8 to 7.7 months); median overall survival was 21.5 months (95% CI, 16.0 to 26.2 months). Best tumor responses were complete response (n = 2 [2%]) and partial response (n = 30 [34%]). During TH-302 maintenance (n = 48), five patients improved from stable disease to partial response, and one patient improved from partial to complete response. The most common adverse events during induction were fatigue, nausea, and skin and/or mucosal toxicities as well as anemia, thrombocytopenia, and neutropenia. These were less severe and less frequent during maintenance. There was no evidence of TH-302–related hepatic, renal, or cardiac toxicity. Conclusion PFS, overall survival, and tumor response compared favorably with historical outcomes achieved with other first-line chemotherapies for advanced STS. A phase III study of TH-302 is ongoing (NCT01440088).
Seroprevalence of Aquaporin-4–IgG in a Northern California Population Representative Cohort of Multiple Sclerosis
Pittock, Sean J. , Lennon, Vanda A. , Bakshi, Nandini, Shen, Ling, McKeon, Andrew , Quach, Hong , Briggs, Farren , Bernstein, Allan , Schaefer, Catherine , Barcellos, Lisa F. , Pittock, S J , McKeon, Andrew , Briggs, Farren Bs

Mayo Clinic

JAMA Neurology | September 1, 2014 | Volume: 71 | Issue: 11 | Pages: 1433

10.1001/jamaneurol.2014.1581 | PMID 25178362 Get It

RVboost: RNA-seq variants prioritization using a boosting method
Wang, Chen , Davila, Jaime , Baheti, Saurabh , Bhagwate, Aditya , Wang, Xue , Kocher, Jean-Pierre A., Feldman, Andrew L. , Novak, Anne J. , Thompson, E. Aubrey , Asmann, Yan W. , Davila, Jaime I, Bhagwate, Aditya V., Slager, Susan L. , Cerhan, James R. , Feldman, Andrew L , Wang, Chen , Davila, Jaime I

Mayo Clinic

Bioinformatics | August 29, 2014 | Volume: 30 | Issue: 23 | Pages: 3414-3416

10.1093/bioinformatics/btu577 | PMID 25170027 Get It

Abstract Motivation: RNA-seq has become the method of choice to quantify genes and exons, discover novel transcripts and detect fusion genes. However, reliable variant identification from RNA-seq data remains challenging because of the complexities of the transcriptome, the challenges of accurately mapping exon boundary spanning reads and the bias introduced during the sequencing library preparation. Method: We developed RVboost, a novel method specific for RNA variant prioritization. RVboost uses several attributes unique in the process of RNA library preparation, sequencing and RNA-seq data analyses. It uses a boosting method to train a model of ‘good quality’ variants using common variants from HapMap, and prioritizes and calls the RNA variants based on the trained model. We packaged RVboost in a comprehensive workflow, which integrates tools of variant calling, annotation and filtering. Results: RVboost consistently outperforms the variant quality score recalibration from the Genome Analysis Tool Kit and the RNA-seq variant-calling pipeline SNPiR in 12 RNA-seq samples using ground-truth variants from paired exome sequencing data. Several RNA-seq–specific attributes were identified as critical to differentiate true and false variants, including the distance of the variant positions to exon boundaries, and the percent of the reads supporting the variant in the first six base pairs. The latter identifies false variants introduced by the random hexamer priming during the library construction. Availability and implementation: The RVboost package is implemented to readily run in Mac or Linux environments. The software and user manual are available at http://bioinformaticstools.mayo.edu/research/rvboost/. Supplementary information: Supplementary data are available at Bioinformatics online.